



(51) International Patent Classification:

C07D 401/14 (2006.01) *A61K 31/4725* (2006.01)
C07D 401/04 (2006.01) *A61P 35/00* (2006.01)
C07D 403/14 (2006.01)

(21) International Application Number:

PCT/US2014/022801

(22) International Filing Date:

10 March 2014 (10.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/776,445 11 March 2013 (11.03.2013) US

(71) Applicants: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). **WANG, Haxia** [US/US]; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US).

(72) Inventors; and

(71) Applicants : **LAWSON, John David** [US/US]; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **SABAT, Mark** [US/US]; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **SCORAH, Nicholas** [GB/US]; Takeda California, Inc., 10410 Science Center Drive, San

Diego, California 92121 (US). **SMITH, Christopher** [GB/US]; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US). **VU, Phong H.** [US/US]; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US).


(74) Agents: **RUSO, Matthew, J.** et al.; Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES



1

(57) Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R¹, R², R³, and R⁴ are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*
GW, KM, ML, MR, NE, SN, TD, TG).